Evaluation of a Screening Strategy for Sarcopenia: a Monocentric Prospective Cohort Study (STRAS)

NCT ID: NCT04827758

Last Updated: 2022-10-28

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-04-22
• Study Completion Date: 2022-09-23

Brief Summary

The main objective of this study is to determine the prevalence of sarcopenia in patients hospitalized in the follow-up care and rehabilitation units of the geriatrics department of the Mulhouse French hospital.

Detailed Description

Secondary objectives

1. To assess the performance of the SARC-F questionnaire to screen for sarcopenia ;

2. To describe the characteristics of sarcopenic patients hospitalized in each follow-up care and rehabilitation unit (i.e. day hospital, full hospitalization);

3. To identify predictive factors of sarcopenia;

4. To determine, in the subgroup of patients hospitalized in the conventional follow-up care and rehabilitation unit (i.e. full hospitalization), the evolution of sarcopenia between admission and discharge of the following variables :

1. muscle strength,

2. muscle mass,

3. functional ability,

4. dependency.

Conduct of research

After receiving the written consent of the study participant, all of the following tests and questionnaires will be performed :

• SARC-F questionnaire,
• measurement of muscle strengh by a grip test,
• measurement of muscle mass by impedancemetry (ASM/size2),
• 4-meter walking speed test,
• Timed-Up and Go (TUG) test,
• ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) questionnaires.

For patients in day hospital care, the study will end upon completion of these tests.

For patients hospitalized in the conventional follow-up care and rehabilitation unit (i.e. full hospitalization), a follow-up visit will be scheduled within 72 hours prior to the patient's discharge from the service, or at 3 months of hospitalization. The following tests and questionnaires will be performed during this visit:

• measurement of muscle strengh by a grip test,
• measurement of muscle mass by impedancemetry,
• 4-meter walking speed test,
• Timed Up and Go (TUG) test,
• ADL and IADL questionnaires.

Conditions

Sarcopenia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Patients hospitalized in the follow-up care and rehabilitation units

Group Type: OTHER

Screening and diagnostic tests for sarcopenia

Intervention Type: PROCEDURE

All of the following tests and questionnaires will be performed :

• SARC-F questionnaire,
• measurement of muscle strengh by a grip test,
• measurement of muscle mass by impedancemetry (ASM/size2),
• 4-meter walking speed test,
• Timed-Up and Go (TUG) test,
• ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) questionnaires.

Interventions

Screening and diagnostic tests for sarcopenia

All of the following tests and questionnaires will be performed :

• SARC-F questionnaire,
• measurement of muscle strengh by a grip test,
• measurement of muscle mass by impedancemetry (ASM/size2),
• 4-meter walking speed test,
• Timed-Up and Go (TUG) test,
• ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) questionnaires.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Patient 60 years of age or older
• Patients hospitalized in the follow-up care and rehabilitation units (i.e. day hospital, full hospitalization) of the geriatrics department of the Mulhouse French hospital
• Patient who gave consent to participate in the study
• Affiliated or beneficiary of a social security scheme

Exclusion Criteria

• Patient admitted for palliative care
• Bedridden patient
• Patient with major neurocognitive disorders preventing impedancemetry or grip test from being performed, or any other medical condition preventing impedancemtery or grip test from being performed
• Patient under legal protection
• Patient with an unstable psychiatric disorder
• Patient under guardianship or curatorship
• Patient already included in the study during a previous hospitalization

• For patients hospitalized in the conventional follow-up care and rehabilitation unit (i.e. full hospitalization), impedancemtry or grip test not performed within 7 days of admission.

Patients excluded secondarily will not be replaced.

• Minimum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Groupe Hospitalier de la Region de Mulhouse et Sud Alsace

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Xavier SIRLIN, MD

Role: PRINCIPAL_INVESTIGATOR

Groupe Hospitalier de la Region de Mulhouse et Sud Alsace

Locations

GHRMSA - Hôpital Emile MULLER

Mulhouse, , France

Countries

France

Other Identifiers

IDRCB 2020-A02364-35

Identifier Type: OTHER

Identifier Source: secondary_id

GHRMSA 1094

Identifier Type: -

Identifier Source: org_study_id